TradingKey

關於 Incyte Corp 公司

Incyte Corporation 是一家生物製藥公司，專注於發現、開發和商業化治療藥物。該公司在兩個治療領域開展業務。一個治療領域是血液學/腫瘤學，包括骨髓增生性腫瘤和移植物抗宿主病，以及實體瘤和血液系統惡性腫瘤。其另一個治療領域是炎症和自身免疫，包括其皮膚病商業特許經營權。其血液學和腫瘤學特許經營權包括六種產品，即 JAKAFI (ruxolitinib)、MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)、PEMAZYRE (pemigatinib)、ICLUSIG (ponatinib)、NIKTIMVO (axatilimab-csfr) 和 ZYNYZ (retifanlimab-dlwr)，以及衆多臨牀開發項目。該公司的產品線還包括兩種一流的 Mas 相關 G 蛋白偶聯受體（MRGPRX2）小分子拮抗劑和口服 MRGPRX4 拮抗劑 INCB000547。

公司簡介

公司代碼INCY

公司名稱Incyte Corp

上市日期Dec 06, 1993

CEOMr. Bill Meury

員工數量2617

證券類型Ordinary Share

年結日Dec 06

公司地址1801 Augustine Cut-Off

城市WILMINGTON

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編19803

電話13024986700

網址https://www.incyte.com/

公司代碼INCY

上市日期Dec 06, 1993

CEOMr. Bill Meury

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

名稱

名稱/職務

職務

持股

持股變動

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

--

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

股東統計

更新時間: 7月19日週六

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

持股股東

佔比

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

股東類型

持股股東

佔比

Investment Advisor

37.07%

Investment Advisor/Hedge Fund

35.74%

Hedge Fund

21.03%

Pension Fund

3.11%

Individual Investor

2.16%

Research Firm

1.99%

Bank and Trust

1.17%

Sovereign Wealth Fund

1.00%

Venture Capital

0.22%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

1417

201.03M

102.93%

+1.34M

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

2023Q1

1294

227.74M

102.15%

-615.23K

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

30.49M

15.75%

+984.00

+0.00%

Jun 30, 2025

The Vanguard Group, Inc.

19.91M

10.29%

+403.13K

+2.07%

Mar 31, 2025

Dodge & Cox

14.86M

7.68%

-55.30K

-0.37%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.92M

6.16%

+257.27K

+2.21%

Mar 31, 2025

State Street Global Advisors (US)

10.04M

5.18%

+4.32K

+0.04%

Mar 31, 2025

AQR Capital Management, LLC

6.74M

3.48%

+3.23M

+92.31%

Mar 31, 2025

Geode Capital Management, L.L.C.

4.21M

2.17%

+167.91K

+4.16%

Mar 31, 2025

Renaissance Technologies LLC

3.71M

1.92%

-377.20K

-9.23%

Mar 31, 2025

LSV Asset Management

3.64M

1.88%

+170.48K

+4.92%

Mar 31, 2025

Invesco Capital Management LLC

2.74M

1.42%

+98.11K

+3.71%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

iShares Genomics Immunology and Healthcare ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.76%

Invesco Biotechnology & Genome ETF

2.77%

SPDR S&P Biotech ETF

2.41%

Bushido Capital US Equity ETF

2.11%

VanEck Biotech ETF

2.07%

Strategas Global Policy Opportunities ETF

1.91%

Virtus LifeSci Biotech Products ETF

1.9%

Invesco S&P 500 Equal Weight Health Care ETF

1.64%

ROBO Global Healthcare Technology & Innovation ETF

1.6%

iShares Genomics Immunology and Healthcare ETF

佔比4.03%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.76%

Invesco Biotechnology & Genome ETF

佔比2.77%

SPDR S&P Biotech ETF

佔比2.41%

Bushido Capital US Equity ETF

佔比2.11%

VanEck Biotech ETF

佔比2.07%

Strategas Global Policy Opportunities ETF

佔比1.91%

Virtus LifeSci Biotech Products ETF

佔比1.9%

Invesco S&P 500 Equal Weight Health Care ETF

佔比1.64%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.6%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Incyte Corp

75.760USD

Incyte Corp

75.760

概覽

公司

財務